Novartis and venture capital firm Versant have set up a new biotech – Borealis Biosciences – using a similar model to their earlier alliance to create Chinook Therapeutics.
Novartis’ bid to build a strong presence in the treatment of rare kidney disease IgA nephropathy (IgAN) has been boosted by phase 3 data with atrasentan, the main asset in
Further evidence of big pharma’s return to M&A dealmaking in 2023 has come this morning from Novartis, which has just agreed a takeover of rival Chinook Therapeutics f
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl